Breaking News Instant updates and real-time market news.

PTI

Proteostasis

$4.17

-0.14 (-3.25%)

, VRTX

Vertex

$181.49

-1.07 (-0.59%)

09:25
03/25/19
03/25
09:25
03/25/19
09:25

Piper sees 'clear rationale' for Phase II studies, stays Overweight Proteostasis

Piper Jaffray analyst Edward Tenthoff lowered his price target for Proteostasis Therapeutics (PTI) to $10 from $14 after the company reported Phase I TripleRx data on PTI-801, potentiator PTI-808 and amplifier PTI-428 in homozygous F508del cystic fibrosis patients showing per protocol ppFEV1 benefit of 5% versus baseline at 14 days. While below the ~10% threshold set by Vertex's (VRTX) Phase III TripleRx trials at 28 days, Proteostasis has a "clear rationale" for planned 28-day Phase II studies of higher dose TripleRx in homozygous and heterozygous F508del patients to start in mid-2019, Tenthoff tells investors in a research note. The analyst, however, lowered his price target for the shares to $10 by pushing out the TripleRx launch to 2022 from 2021. He keeps an Overweight rating on the name. Proteostasis in premarket trading is down 52%, or $2.12, to $1.95.

PTI

Proteostasis

$4.17

-0.14 (-3.25%)

VRTX

Vertex

$181.49

-1.07 (-0.59%)

  • 25

    Mar

  • 10

    Apr

PTI Proteostasis
$4.17

-0.14 (-3.25%)

11/07/18
CANT
11/07/18
INITIATION
Target $21
CANT
Overweight
Cantor sees 'clear opportunity' for Proteostasis, starts at Overweight
Cantor Fitzgerald analyst Elemer Piros last night initiated coverage of Proteostasis (PTI) with an Overweight rating and $21 price target. Proteostasis is developing CFTR modulator therapies for the treatment of cystic fibrosis, Piros tells investors in a research note. The analyst sees a "clear opportunity" for Proteostasis to carve out a good portion of the market and make a name for itself in CF. Vertex (VRTX) has opened the door for developing CFTR modulators, says Piros.
11/07/18
PIPR
11/07/18
NO CHANGE
Target $14
PIPR
Overweight
Piper Jaffray sees 'huge valuation disconnect' between Proteostasis, Vertex
Piper Jaffray analyst Edward Tenthoff notes that Proteostasis (PTI) ended Q3 with cash of $46M million subsequently completed an equity financing and sold 1.4M shares through an ATM, bringing pro forma cash to about $138M, which he estimates will fund the company into 2020. The primary driver remains initial Phase I data on Proteostasis' proprietary TripleRx regimen in homozygous F508del Cystic Fibrosis this quarter, he contends, adding that he remains encouraged based on recently reported positive Phase I data on proprietary CFTR potentiator PTI-808 and corrector PTI-801 in homozygous F508del CF patients. The analyst sees a "huge valuation disconnect" between Proteostasis and CF market leader Vertex (VRTX), and reiterates an Overweight rating and $14 price target on the former's shares.
11/07/18
11/07/18
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Linde plc (LIN) initiated with a Market Perform at BMO Capital. 2. Posco (PKX) initiated with an Equal Weight at Morgan Stanley. 3. Proteostasis (PTI) initiated with an Overweight at Cantor Fitzgerald. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/17/18
PIPR
12/17/18
NO CHANGE
PIPR
Proteostasis deal with Genentech strenghtens balance sheet, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $14 price target on Proteostasis (PTI), noting the company announced an agreement with Roche's (RHHBY) Genentech to license small molecule modulators of an undisclosed target that lie outside of Cystic Fibrosis, which makes the company eligible for $100M in upfront and milestone payments plus royalties. Tenthoff sees this deal strengthening Proteostasis' balance sheet. Additionally, Tenthoff is optimistic on Proteostasis' TripleRx combo, and expects full Phase I TripleRx data in Q1 of 2019. Longer term, the analyst anticipates TripleRx approval in 2021, with global sales of $2.0B by 2026.
VRTX Vertex
$181.49

-1.07 (-0.59%)

03/07/19
OPCO
03/07/19
NO CHANGE
Target $230
OPCO
Outperform
Vertex price target raised to $230 from $200 at Oppenheimer
Oppenheimer analyst Hartaj Singh raised his price target for Vertex to $230 from $200 after the company reported a successful phase 3 program for efficacy for the VX-445 triplet regimen. Like the successful phase 3 VX-659 triplet program reported in late November, VX-445 efficacy continues to be solid, he contended, adding however that only a minority of hetmin F508del patients had passed the 24-week safety evaluation, forcing Vertex to wait and review this data in Q2 before choosing a candidate for regulatory filings. Singh review of the VX-659 and VX-445 phase 1/2 studies, management commentary and the positive tone around safety in the press release lead him to believe Vertex has one candidate that can be filed. He reiterates an Outperform rating on the shares.
03/19/19
LEER
03/19/19
DOWNGRADE
LEER
Market Perform
Vertex downgraded to Market Perform from Outperform at SVB Leerink
03/19/19
03/19/19
DOWNGRADE
Target $170

Market Perform
Vertex downgraded to Market Perform on EU impasse, full valuation at SVB Leerink
As previously reported, SVB Leerink analyst Geoffrey Porges downgraded Vertex to Market Perform from Outperform, citing the slower ramp of the company's cystic fibrosis products in Europe and the continued resistance of payers there, the already high expectations priced into the stock and evident in consensus forecasts, and the limited near-term opportunities and catalysts from the company's pipeline. Overall, the analyst sees the stock's recent strength as consistent with his positive view, but now reflecting most of the realistic value of the company's identifiable product opportunities for cystic fibrosis. Porges also lowered his price target on the shares to $170 from $183.
03/19/19
03/19/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. ImmunoGen (IMGN) downgraded to Underweight from Neutral at JPMorgan with analyst Jessica Fye saying the failure of Forward I is a "meaningful setback" for the mirvetuximab development program. 2. Vertex (VRTX) downgraded to Market Perform from Outperform at SVB Leerink with analyst Geoffrey Porges citing the slower ramp of the company's cystic fibrosis products in Europe, the already high expectations priced into the stock and the limited near-term opportunities and catalysts from the company's pipeline. 3. iRobot (IRBT) downgraded to Hold from Buy at Needham with analyst James Ricchiuti stating the market appears to be pricing in expectations of "meaningful upside" to the company's 2019 guidance after the run-up in its stock price this year. 4. Yum! Brands (YUM) downgraded to Neutral from Overweight at JPMorgan with analyst John Ivankoe saying the 9% year-to-date run in shares leaves little upside to estimates. 5. Boeing (BA) downgraded to Hold from Buy at Argus with analyst John Eade stating that he believes company management has not been particularly proactive in its response to two fatal crashes involving the 737 Max jet. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

KO

Coca-Cola

$48.18

0.8 (1.69%)

, UTX

United Technologies

$140.11

3.12 (2.28%)

12:30
04/23/19
04/23
12:30
04/23/19
12:30
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks have been boosted…

KO

Coca-Cola

$48.18

0.8 (1.69%)

UTX

United Technologies

$140.11

3.12 (2.28%)

VZ

Verizon

$57.06

-1.32 (-2.26%)

PG

Procter & Gamble

$103.21

-2.83 (-2.67%)

TWTR

Twitter

$40.12

5.73 (16.66%)

KSS

Kohl's

$73.38

5.95 (8.82%)

AMZN

Amazon.com

$1,927.44

39.34 (2.08%)

HAS

Hasbro

$101.54

13.52 (15.36%)

CROX

Crocs

$26.45

-0.8 (-2.94%)

WAT

Waters

$210.23

-30.85 (-12.80%)

STT

State Street

$67.15

-2.77 (-3.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 24

    Apr

  • 25

    Apr

  • 29

    Apr

  • 02

    May

  • 07

    May

  • 07

    May

  • 10

    May

  • 14

    May

  • 15

    May

  • 15

    May

  • 16

    May

  • 16

    May

  • 20

    May

  • 20

    May

  • 21

    May

  • 22

    May

  • 29

    May

  • 03

    Jun

  • 11

    Jun

BAC

Bank of America

$30.15

0.09 (0.30%)

12:30
04/23/19
04/23
12:30
04/23/19
12:30
Options
Aggressive call buy in BofA weekly contracts »

Aggressive call buy in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 14

    May

  • 29

    May

  • 03

    Jun

  • 11

    Jun

  • 17

    Jul

BA

Boeing

$374.75

-0.27 (-0.07%)

, ERJ

Embraer

$19.89

0.11 (0.56%)

12:27
04/23/19
04/23
12:27
04/23/19
12:27
On The Fly
Fly Intel: What to watch in Boeing's earnings report »

Boeing (BA) is scheduled…

BA

Boeing

$374.75

-0.27 (-0.07%)

ERJ

Embraer

$19.89

0.11 (0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 29

    Apr

  • 29

    May

  • 05

    Jun

GOOGL

Alphabet Class A

$1,273.21

19.27 (1.54%)

, GOOG

Alphabet

$1,267.21

18.25 (1.46%)

12:27
04/23/19
04/23
12:27
04/23/19
12:27
Recommendations
Alphabet Class A, Alphabet analyst commentary at Baird »

Alphabet Q1 revenue to…

GOOGL

Alphabet Class A

$1,273.21

19.27 (1.54%)

GOOG

Alphabet

$1,267.21

18.25 (1.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

  • 29

    Apr

  • 14

    May

  • 27

    Oct

UNM

Unum Group

$37.22

0.83 (2.28%)

12:25
04/23/19
04/23
12:25
04/23/19
12:25
Options
Unum Group call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 23

    May

  • 11

    Jun

12:25
04/23/19
04/23
12:25
04/23/19
12:25
General news
Oil Action: WTI crude's »

Oil Action: WTI…

NVDA

Nvidia

$191.80

3.32 (1.76%)

, AMD

AMD

$27.97

-0.2 (-0.71%)

12:21
04/23/19
04/23
12:21
04/23/19
12:21
Hot Stocks
Gaming stocks get a jolt after Nvidia introduces 'turbocharged' laptop GPUs »

Shares of companies in…

NVDA

Nvidia

$191.80

3.32 (1.76%)

AMD

AMD

$27.97

-0.2 (-0.71%)

MSFT

Microsoft

$124.97

1.21 (0.98%)

DELL

Dell Technologies

$63.98

0.75 (1.19%)

GME

GameStop

$8.94

0.29 (3.35%)

EA

Electronic Arts

$94.96

2.47 (2.67%)

ATVI

Activision Blizzard

$46.62

1.3 (2.87%)

SNE

Sony

$48.16

0.55 (1.16%)

AAPL

Apple

$207.00

2.38 (1.16%)

TTWO

Take-Two

$93.70

1.81 (1.97%)

ADBE

Adobe

$277.10

4.87 (1.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

  • 26

    Apr

  • 30

    Apr

  • 30

    Apr

  • 02

    May

  • 07

    May

  • 08

    May

  • 13

    May

  • 15

    May

  • 22

    May

  • 29

    May

  • 30

    May

  • 03

    Jun

  • 03

    Jun

  • 08

    Jun

  • 10

    Jun

  • 23

    Jun

  • 06

    Aug

  • 13

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
04/23/19
04/23
12:17
04/23/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
04/23/19
04/23
12:16
04/23/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EBAY

eBay

$36.68

0.53 (1.47%)

, GOOG

Alphabet

$1,265.27

16.31 (1.31%)

12:12
04/23/19
04/23
12:12
04/23/19
12:12
Earnings
Fly Intel: What to watch in eBay earnings report »

eBay (EBAY) is scheduled…

EBAY

eBay

$36.68

0.53 (1.47%)

GOOG

Alphabet

$1,265.27

16.31 (1.31%)

GOOGL

Alphabet Class A

$1,271.09

17.15 (1.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 29

    Apr

  • 29

    Apr

  • 14

    May

  • 27

    Oct

MDR

McDermott

$10.29

0.08 (0.78%)

12:10
04/23/19
04/23
12:10
04/23/19
12:10
Options
Ratio spread in McDermott as a defensive position is adjusted »

Ratio spread in McDermott…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

  • 02

    May

FSLR

First Solar

$61.54

1.57 (2.62%)

12:05
04/23/19
04/23
12:05
04/23/19
12:05
Options
First Solar call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

  • 17

    May

FANG

Diamondback Energy

$111.74

0.58 (0.52%)

12:03
04/23/19
04/23
12:03
04/23/19
12:03
Recommendations
Diamondback Energy analyst commentary at Roth Capital »

Diamondback Energy price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

SNAP

Snap

$12.08

0.55 (4.77%)

, FB

Facebook

$183.09

1.6 (0.88%)

11:59
04/23/19
04/23
11:59
04/23/19
11:59
Earnings
On The Fly: What to watch in Snap earnings report »

Snap Inc. (SNAP) is…

SNAP

Snap

$12.08

0.55 (4.77%)

FB

Facebook

$183.09

1.6 (0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

  • 03

    Jun

WVE

Wave Life Sciences

$27.21

1.43 (5.55%)

11:50
04/23/19
04/23
11:50
04/23/19
11:50
Options
Call buy in Wave Life will create its largest open interest »

Call buy in Wave Life…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:50
04/23/19
04/23
11:50
04/23/19
11:50
General news
Treasury's $26 B 52-week bill results were very strong »

Treasury's $26 B…

FELE

Franklin Electric

$48.00

-3.16 (-6.18%)

11:47
04/23/19
04/23
11:47
04/23/19
11:47
Earnings
Franklin Electric backs FY19 EPS ex-restructuring charges view $2.37-$2.47 »

Consensus $2.40. "As…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 03

    May

FELE

Franklin Electric

$47.99

-3.17 (-6.20%)

11:43
04/23/19
04/23
11:43
04/23/19
11:43
Downgrade
Franklin Electric rating change at Boenning & Scattergood »

Franklin Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 03

    May

AVP

Avon Products

$2.68

0.08 (3.08%)

11:40
04/23/19
04/23
11:40
04/23/19
11:40
Options
Call buyer in Avon as shares snap a seven-day losing skid »

Call buyer in Avon as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 16

    May

HRL

Hormel Foods

$39.38

-1.06 (-2.62%)

, SJM

J.M. Smucker

$121.47

0.26 (0.21%)

11:39
04/23/19
04/23
11:39
04/23/19
11:39
On The Fly
Analysts say sell Hormel Foods on pork costs amid African swine fever outbreak »

Shares of Hormel Foods…

HRL

Hormel Foods

$39.38

-1.06 (-2.62%)

SJM

J.M. Smucker

$121.47

0.26 (0.21%)

TSN

Tyson Foods

$73.90

1.09 (1.50%)

BRFS

BRF S.A.

$7.53

0.425 (5.99%)

SAFM

Sanderson Farms

$143.52

1.95 (1.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 18

    May

  • 28

    May

  • 29

    May

  • 30

    May

  • 13

    Nov

11:36
04/23/19
04/23
11:36
04/23/19
11:36
General news
52-Week Bill Auction Bid/Cover data reported »

52-Week Bill Auction…

11:36
04/23/19
04/23
11:36
04/23/19
11:36
General news
52-Week Bill Auction Total Amount data reported »

52-Week Bill Auction…

EROS

Eros International

$8.15

0.13 (1.62%)

11:30
04/23/19
04/23
11:30
04/23/19
11:30
Hot Stocks
Eros Now announces distribution deal with TCL Electronics »

Eros Now announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    May

LMT

Lockheed Martin

$336.20

20.96 (6.65%)

11:27
04/23/19
04/23
11:27
04/23/19
11:27
Hot Stocks
Breaking Hot Stocks news story on Lockheed Martin »

Lockheed Martin sees tax…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 25

    Apr

  • 29

    May

  • 05

    Jun

COP

ConocoPhillips

$67.23

0.245 (0.37%)

11:25
04/23/19
04/23
11:25
04/23/19
11:25
Options
ConocoPhillips call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 14

    May

  • 22

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.